Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd (ZTEK) delivers cutting-edge innovations in healthcare technology and advanced materials through its patented intellectual property portfolio. This news hub provides investors and industry observers with timely updates on corporate developments, regulatory milestones, and commercial partnerships.
Access verified press releases and analysis covering ZenGUARD™ antimicrobial advancements, battery material research, and strategic collaborations with academic institutions. Our curated feed ensures transparent tracking of financial announcements, product launches, and intellectual property expansions.
Key updates include earnings reports, technology licensing agreements, and progress in graphite purification techniques for energy storage applications. Bookmark this page to monitor Zentek's progress in enhancing medical safety standards and sustainable material solutions.
Rhea-AI Summary
Zentek announces positive preclinical results for its C19HBA SARS-CoV-2 universal aptamer, showing promising safety and efficacy profiles. The testing conducted by Triera Biosciences demonstrated that C19HBA matched or exceeded clinical protection compared to a leading monoclonal antibody. The study, led by Dr. Miller at McMaster University, revealed that C19HBA was safe and well-tolerated in mice, without inducing unexpected inflammatory responses. These results indicate a significant step towards developing a human therapeutic for COVID-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
-
Rhea-AI Summary
Zentek Ltd. announces successful preclinical testing of its C19HBA aptamer as a potential therapeutic for SARS-CoV-2, outperforming a leading monoclonal antibody in trials. The aptamer demonstrated improved therapeutic benefits in mice, showing signs of recovery one day earlier and a 30% reduction in total average weight loss compared to the control groups. The company plans to move C19HBA towards phase 1 clinical trials for COVID-19 and explore other potential partnerships for the platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.8%
Tags
-
News
Rhea-AI Summary
Zentek Ltd. announces the completion of a study demonstrating significant energy, emission, and cost savings for commercial buildings adopting ZenGUARDTM Enhanced Air Filters. The study revealed that using ZenGUARDTM filters can reduce HVAC energy consumption by approximately 62%, resulting in monetary savings of approximately $12,400 per year and avoidance of 32 tonnes of CO2 emissions per year for each office space. The company estimates that energy consumption within the Canadian Federal Public Service could be reduced by 455.7 million kWh, translating to monetary savings of $68.4 million per year and an avoidance of approximately 58,200 tonnes of CO2 emissions per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Zentek Ltd. announces the resignation of Dr. Francis Dubé as Chairman of the Board, appointing Mr. Eric Wallman as the new Chairman. Mr. Wallman, an independent director since 2018, will uphold best governance practices. Dr. Dubé will continue as a director and Chief Operating Officer. CEO Greg Fenton expresses gratitude towards Dr. Dubé and Mr. Wallman for their roles in governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Zentek Ltd. (ZTEK) announces the launch of Triera Biosciences Ltd. as its wholly owned subsidiary for aptamer platform technology. Triera will focus on developing a treatment for the SARS-CoV-2 virus, including the Omicron XBB 1.5 variant, and a rapid detection platform. The company aims to create a standalone entity to attract potential pharmaceutical partners and funders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Zentek Ltd. (Zentek) (Nasdaq:ZTEK)(TSX-V:ZEN) and 1Click Heating and Cooling Inc. (1Click) have signed a distribution agreement for ZenGUARD™ enhanced viral filtration efficiency MERV 9 rated filters. The agreement capitalizes on the growing global heat pump market, with 1Click positioned to benefit from significant financial incentives for heat pump installations in Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
Rhea-AI Summary
Zentek Ltd. (ZTEK) grants 400,000 options to a director and officer, exercisable at $1.75 per share, with vesting over three to five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
Zentek Ltd. (ZTEK) announces successful testing of its COVID-19 High-Binding Affinity (C19HBA) aptamer against the Omicron XBB 1.5 variant, showing comparable performance to monoclonal antibodies. The company aims to leverage its platform for the development of new therapeutics, exploring partnership opportunities in the pharmaceutical space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.54%
Tags
-
Rhea-AI Summary
Zentek Ltd. (ZTEK) provides an update on its wholly owned subsidiary Albany Graphite Corp., intending to transfer its Albany Graphite Deposit to a subsidiary and complete a proposed private placement financing. However, due to deteriorating market conditions for battery metals and graphite, the company has decided to wait for improved market conditions before proceeding with the Private Placement and/or Listing. The company continues to believe in the long-term value and potential of the Albany Graphite Deposit, and management intends to continue evaluating potential financing and partnership opportunities. Brian Bosse has ceased to act as the CEO of Albany Graphite Corp., and Greg Fenton has been appointed as the interim CEO. Zentek expects the Albany Graphite Project to combine the higher performance metrics of synthetic graphite with the much lower carbon footprint offered by natural graphite, sourced in North America, to meet the increasing demand for North American sourced graphite.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
Rhea-AI Summary
Zentek Ltd. (ZTEK) Announces Major Upgrade to Aptamer Platform, Boosting Covid-19 Therapeutic Potential. The company has developed a significant upgrade to its aptamer platform, increasing the binding affinity of the universal Covid-19 aptamer and solving key manufacturing challenges. Zentek's HBA aptamers are now produced with a 95% yield, offering cost-effective and high-purity manufacturing. The company has filed a new provisional patent to protect this latest innovation. Zentek aims to explore oncology and immunology research, leveraging its aptamer platform. The company's HBA aptamer for SARS-CoV-2 has shown strong therapeutic potential and is estimated to require $1.0 million to complete the pre-clinical program and enter clinical trials. Zentek's CEO and Independent Director highlight the promising future of the aptamer platform in drug development and welcome Mr. John Snisarenko to the Board of Directors, bringing significant pharmaceutical industry experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
Zentek Ltd